Effective Treatments Identified for Pediatric Complication of COVID
PHOENIX — First-line treatment with methylprednisolone and second-line treatment with tocilizumab (Actemra) shortened hospital stays for children with pediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS; also referred to as multisystem inflammatory syndrome in children [MIS-C]), according to results of a two-stage clinical trial from the RECOVERY collaborative group. In 214 children randomly assigned […]
Studies Question Role of CDK4/6 Inhibitors in First-Line Advanced Breast Cancer
CHICAGO — Upfront CDK4/6 inhibition or second-line use in advanced hormone receptor (HR)-positive/HER2-negative breast cancer led to similar cumulative progression-free survival (PFS) in a large randomized trial. Patients who received a CDK4/6 inhibitor plus an aromatase inhibitor (AI) as initial therapy and fulvestrant in the second line had a median PFS of 31.0 months at […]
Second-Line CAR-T Impresses in Transplant-Ineligible Large B-Cell Lymphoma
Treatment with second-line lisocabtagene maraleucel (liso-cel; Breyanzi) yielded a response rate of 80% for patients with relapsed or refractory large B-cell lymphoma (LBCL) who were not candidates for hematopoietic stem cell transplant, the phase II PILOT study showed. Among 61 evaluable patients with PET-positive disease, 54% achieved a complete response with the chimeric antigen receptor […]
Early Promise for Pembrolizumab Plus Chemo in RR Hodgkin’s Lymphoma
A chemoimmunotherapy regimen led to a 100% response rate as second-line therapy for relapsed/refractory (RR) classical Hodgkin lymphoma (cHL), a small phase II trial showed. All 38 evaluable patients achieved objective responses with the combination of pembrolizumab (Keytruda), gemcitabine, vinorelbine, and liposomal doxorubicin (P-GVD), including complete responses in 36 of 38 cases. All but two […]